

Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

This article was originally published [here](#)

MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients

The post [Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy](#) appeared first on [Pharmaceutical Business review](#).